TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
TC Biopharm (Holdings) PLC (NASDAQ: TCBP) announced that CEO Bryan Kobel will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 am. The company is focused on developing allogeneic gamma-delta T cell therapies for cancer treatment and is conducting pivotal clinical trials, including a Phase 2b/3 trial for OmnImmune® in acute myeloid leukemia. A webcast of the presentation will be available on TC BioPharm's Investor Relations page.
- None.
- None.
EDINBURGH, Scotland, Aug. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that Chief Executive Officer, Bryan Kobel will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, on Monday, September 12th at 7:00 am.
A webcast of the presentation will be available on the Investor Relations page of TC BioPharm's website. For more information or schedule a 1X1 meeting with management, please visit; https://hcwevents.com/annualconference/
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia and Phase I trial for ImmuniStim in treatment of Covid patients using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors and a significant IP/patent portfolio in the use of CARs with gamma delta t-cells and owns our manufacturing facility to maintain cost and product quality controls.
Forward Looking Statements
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301609516.html
SOURCE TC BioPharm
FAQ
When will TC Biopharm present at the H.C. Wainwright 24th Annual Global Investment Conference?
Who will represent TC Biopharm at the conference?
What is the focus of TC Biopharm's therapies?
What clinical trials is TC Biopharm currently conducting?
Where can I find the webcast of TC Biopharm's conference presentation?
